Pentoxifylline down modulate in vitro T cell responses and attenuate pathology in Leishmania and HTLV-I infections

International Immunopharmacology

Volumn 8, Issue 10, 2008, Pages 1344-1353

  Ribeiro de Jesus, Amelia ^a,b   Luna, Tânia ^a   Pacheco de Almeida, Roque ^a,b   Machado, Paulo Roberto Lima ^a   Carvalho, Edgar M ^a  

^a FEDERAL UNIVERSITY OF BAHIA   (Brazil)

^b FEDERAL UNIVERSITY OF SERGIPE   (Brazil)

Author keywords

Cutaneous leishmaniasis; HTLV 1; Immunotherapy; Leishmaniasis; Mucosal leishmaniasis; Pentoxifylline

Indexed keywords

ANTIMONY; GAMMA INTERFERON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PENTOXIFYLLINE; TRANSCRIPTION FACTOR NFAT; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CLINICAL TRIAL; CYTOKINE PRODUCTION; HUMAN; HUMAN T CELL LEUKEMIA VIRUS 1; HUMAN T CELL LEUKEMIA VIRUS INFECTION; IMMUNOMODULATION; IMMUNOPATHOGENESIS; LYMPHOCYTE CULTURE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; SKIN LEISHMANIASIS; SYSTEMATIC REVIEW; T LYMPHOCYTE;

ANIMALS; HTLV-I INFECTIONS; HUMANS; INTERFERON TYPE II; LEISHMANIA; LEISHMANIASIS; PENTOXIFYLLINE; T-LYMPHOCYTES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 50949098467     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.intimp.2008.03.020     Document Type: Article

References (97)

1. Kollias G., Douni E., Kassiotis G., and Kontoyiannis D. The function of tumour necrosis factor and receptors in models of multi-organ inflammation, rheumatoid arthritis, multiple sclerosis and inflammatory bowel disease. Ann Rheum Dis 58 Suppl 1 (Nov 1999) I32-I39
2. Martin J.F.B., Jiménez J.L., and Munoz-Fernández M.A. Pentoxifylline and severe acute respiratory syndrome (SARS): a drug to be considered. Med Sci Monit 9 6 (2003) SR41-SR46
3. Kassiotis G., and Kollias G. Uncoupling the proinflammatory from the immunosuppressive properties of tumor necrosis factor (TNF) at the p55 TNF receptor level: implications for pathogenesis and therapy of autoimmune demyelination. J Exp Med 193 4 (2001 Feb 19) 427-434
4. Konstantinos A.P. Tumor necrose factor: biology and therapeutic inhibitors. Gastroenterology 119 4 (2000) 1148-1157
5. Ryffel B., Brockhaus M., Greiner B., Mihatsch M.J., and Gudat F. Tumour necrosis factor receptor distribution in human lymphoid tissue. Immunology 74 3 (1991 Nov) 446-452
6. Blam M.E., Stein R.B., and Lichtenstein G.R. Integrating anti-tumor necrosis factor therapy in inflammatory bowel disease: current and future perspectives. Am J Gastroenterol 96 7 (July 2001) 1977-1997
7. Witkamp R., and Monshouwer M. Signal transduction in inflammatory processes, current and future therapeutic targets: a mini review. Vet Q 22 1 (Jan 2000) 11-16
8. Feldmann M., Brennan F.M., and Maini R.N. Role of cytokines in rheumatoid arthritis. Annu Rev Immunol 14 (1996) 397-440
9. Reilly M.P., Rohatgi A., McMahon K., Wolfe M.L., Pinto S.C., Rhodes T., et al. Plasma cytokines, metabolic syndrome, and atherosclerosis in humans. J Investig Med 55 1 (Jan 2007) 26-35
10. Rozieres A., Hennino A., and Nicolas J.F. [TNF alpha in the physiopathology of psoriasis]. Ann Dermatol Venereol 133 2 (Feb 2006) 174-180
11. Poiesz B.J., Ruscetti F.W., Gazdar A.F., Bunn P.A., Minna J.D., and Gallo R.C. Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc Natl Acad Sci U S A 77 12 (Dec 1980) 7415-7419
12. Osame M., Usuku K., Izumo S., Ijichi N., Amitani H., Igata A., et al. HTLV-I associated myelopathy, a new clinical entity. Lancet 1 8488 (May 3 1986) 1031-1032
13. Edlich R.F., Hill L.G., and Williams F.M. Global epidemic of human T-cell lymphotrophic virus type-I (HTLV-I): an update. J. Long-term Eff. Med. Implants 13 2 (2003) 127-140
14. Azimi N., Nagai M., Jacobson S., and Waldmann T.A. IL-15 plays a major role in the persistence of Tax-specific CD8 cells in HAM/TSP patients. Proc Natl Acad Sci U S A 98 25 (Dec 4 2001) 14559-14564
15. Jacobson S. Immunopathogenesis of human T cell lymphotropic virus type I-associated neurologic disease. J Infect Dis 186 Suppl 2 (Dec 1 2002) S187-S192
16. Nagai M., Kubota R., Greten T.F., Schneck J.P., Leist T.P., and Jacobson S. Increased activated human T cell lymphotropic virus type I (HTLV-I) Tax11-19-specific memory and effector CD8+ cells in patients with HTLV-I-associated myelopathy/tropical spastic paraparesis: correlation with HTLV-I provirus load. J Infect Dis 183 2 (Jan 15 2001) 197-205
17. Nagai M., Usuku K., Matsumoto W., Kodama D., Takenouchi N., Moritoyo T., et al. Analysis of HTLV-I proviral load in 202 HAM/TSP patients and 243 asymptomatic HTLV-I carriers: high proviral load strongly predisposes to HAM/TSP. J Neurovirol 4 6 (Dec 1998) 586-593
18. Guerreiro J.B., Santos S.B., Morgan D.J., Porto A.F., Muniz A.L., Ho J.L., et al. Levels of serum chemokines discriminate clinical myelopathy associated with human T lymphotropic virus type 1 (HTLV-1)/tropical spastic paraparesis (HAM/TSP) disease from HTLV-1 carrier state. Clin Exp Immunol 145 2 (Aug 2006) 296-301
19. Nagai M., and Osame M. Human T-cell lymphotropic virus type I and neurological diseases. J Neurovirol 9 2 (Apr 2003) 228-235
20. Santos S.B., Porto A.F., Muniz A.L., de Jesus A.R., Magalhaes E., Melo A., et al. Exacerbated inflammatory cellular immune response characteristics of HAM/TSP is observed in a large proportion of HTLV-I asymptomatic carriers. BMC Infect Dis 2 4 (Mar 2004) 7
21. Hickey W.F., Hsu B.L., and Kimura H. T-lymphocyte entry into the central nervous system. J Neurosci Res 28 2 (Feb 1991) 254-260
22. Narikawa K., Fujihara K., Misu T., Feng J., Fujimori J., Nakashima I., et al. CSF-chemokines in HTLV-I-associated myelopathy: CXCL10 up-regulation and therapeutic effect of interferon-alpha. J Neuroimmunol 159 1-2 (2005 Feb) 177-182
23. Santos S.B., Porto A.F., Muniz A.L., Luna T., Nascimento M.C., Guerreiro J.B., et al. Modulation of T cell responses in HTLV-1 carriers and in patients with myelopathy associated with HTLV-1. Neuroimmunomodulation 13 3 (2006) 145-151
24. Osame M. Pathological mechanisms of human T-cell lymphotropic virus type I-associated myelopathy (HAM/TSP). J Neurovirol 8 5 (Oct 2002) 359-364
25. Castro N.M., Freitas D.M., Rodrigues Jr. W., Muniz A., Oliveira P., and Carvalho E.M. Urodynamic features of the voiding dysfunction in HTLV-1 infected individuals. Int Braz J Urol 33 (2007) 238-244 discussion 44-5.
26. Castro N.M., Rodrigues W.J., Freitas D.M., Muniz A., Oliveira P., and Carvalho E.M. Urinary symptoms associated with human T-cell lymphotropic virus type I infection: evidence of urinary manifestations in large group of HTLV-I carriers. Urology 69 (2007) 813-818
27. Araújo A. Progression of neurological disability in HTLV-I-associated myelopathy/tropical spastic paraparesis (HAM/TSP). Neurol Sci 129 (1995) 147-151
28. Araujo A de Q., Alfonso C.R., Schor D., Leite A.C., and de Andrada-Serpa M.J. Clinical and demographic features of HTLV-1 associated myelopathy/tropical spastic paraparesis (HAM/TSP) in Rio de Janeiro, Brazil. Acta Neurol Scand 88 (1993) 59-62
29. Desjeux P. Leishmaniasis: current situation and new perspectives. Comp Immunol Microbiol Infect Dis 27 5 (Sep 2004) 305-318
30. Almeida R.P., Barral-Netto M., De Jesus A.M., De Freitas L.A., Carvalho E.M., and Barral A. Biological behavior of Leishmania amazonensis isolated from humans with cutaneous, mucosal, or visceral leishmaniasis in BALB/C mice. Am J Trop Med Hyg 54 2 (1996) 178-184
31. Cupolillo E., Grimaldi Jr. G., and Momen H. Genetic diversity among Leishmania (Viannia) parasites. Ann Trop Med Parasitol 91 6 (1997) 617-626
32. Schriefer A., Schriefer A.L., Goes-Neto A., Guimaraes L.H., Carvalho L.P., Almeida R.P., et al. Multiclonal Leishmania braziliensis population structure and its clinical implication in a region of endemicity for American tegumentary leishmaniasis. Infect Immun 72 1 (2004 Jan) 508-514
33. Bacellar O., Lessa H., Schriefer A., Machado P., Ribeiro De Jesus A., Dutra W.O., et al. Up-regulation of Th1-type responses in mucosal leishmaniasis patients. Infect Immun 70 12 (2002) 6734-6740
34. Blackwell J.M., Black G.F., Peacock C.S., Miller E.N., Sibthorpe D., Gnananandha D., et al. Immunogenetics of leishmanial and mycobacterial infections: the Belem Family Study. Philos Trans R Soc Lond B Biol Sci 352 1359 (1997) 1331-1345
35. Cabrera M., Shaw M.A., Sharples C., Williams H., Castes M., Convit J., et al. Polymorphism in tumor necrosis factor genes associated with mucocutaneous leishmaniasis. J Exp Med 182 5 (1995) 1259-1264
36. Castellucci L., Menezes E., Oliveira J., Magalhaes A., Guimaraes L.H., Lessa M., et al. IL6-174 G/C promoter polymorphism influences susceptibility to mucosal but not localized cutaneous leishmaniasis in Brazil. J Infect Dis 194 4 (Aug 15 2006) 519-527
37. Follador I., Araujo C., Bacellar O., Araujo C.B., Carvalho L.P., Almeida R.P., et al. Epidemiologic and immunologic findings for the subclinical form of Leishmania braziliensis infection. Clin Infect Dis 34 11 (2002) E54-E58
38. Karplus T.M., Jeronimo S.M., Chang H., Helms B.K., Burns T.L., Murray J.C., et al. Association between the tumor necrosis factor locus and the clinical outcome of Leishmania chagasi infection. Infect Immun 70 12 (2002) 6919-6925
39. Turetz M.L., Machado P.R., Ko A.I., Alves F., Bittencourt A., Almeida R.P., et al. Disseminated leishmaniasis: a new and emerging form of leishmaniasis observed in northeastern Brazil. J Infect Dis 186 12 (Dec 15 2002) 1829-1834
40. Titus R.G., and Ribeiro J.M. Salivary gland lysates from the sand fly Lutzomyia longipalpis enhance Leishmania infectivity. Science 239 4845 (1988) 1306-1308
41. Desjeux P. Human leishmaniases: epidemiology and public health aspects. World Health Stat Q 45 2-3 (1992) 267-275
42. Grimaldi Jr. G., and Tesh R.B. Leishmaniases of the New World: current concepts and implications for future research. Clin Microbiol Rev 6 3 (1993) 230-250
43. Lainson R. The American leishmaniases: some observations on their ecology and epidemiology. Trans R Soc Trop Med Hyg 77 5 (1983) 569-596
44. Jones T.C., Johnson Jr. W.D., Barretto A.C., Lago E., Badaro R., Cerf B., et al. Epidemiology of American cutaneous leishmaniasis due to Leishmania braziliensis braziliensis. J Infect Dis 156 1 (1987) 73-83
45. Ben Salah A., Louzir H., Chlif S., Mokni M., Zaatour A., Raouene M., et al. The predictive validity of naturally acquired delayed-type hypersensitivity to leishmanin in resistance to Leishmania major-associated cutaneous leishmaniasis. J Infect Dis 192 11 (Dec 1 2005) 1981-1987
46. Follador I., Araujo C., Cardoso M.A., Tavares-Neto J., Barral A., Miranda J.C., et al. [Outbreak of American cutaneous leishmaniasis in Canoa, Santo Amaro, Bahia, Brazil]. Rev Soc Bras Med Trop 32 5 (1999) 497-503
47. Carvalho E.M. Cell mediated immunity in American cutaneous and mucosal leishmaniasis. J Immunol 135 (1985) 4144-4148
48. Carvalho E.M., Johnson W.D., Barreto E., Marsden P.D., Costa J.L., Reed S., et al. Cell mediated immunity in American cutaneous and mucosal leishmaniasis. J Immunol 135 6 (1985) 4144-4148
49. Ribeiro-de-Jesus A., Almeida R.P., Lessa H., Bacellar O., and Carvalho E.M. Cytokine profile and pathology in human leishmaniasis. Braz J Med Biol Res 31 1 (1998) 143-148
50. Sacks D., and Noben-Trauth N. The immunology of susceptibility and resistance to Leishmania major in mice. Nat Rev Immunol 2 11 (Nov 2002) 845-858
51. Sher A., Gazzinelli R.T., Oswald I.P., Clerici M., Kullberg M., Pearce E.J., et al. Role of T-cell derived cytokines in the downregulation of immune responses in parasitic and retroviral infection. Immunol Rev 127 (1992) 183-204
52. Bomfim G., Nascimento C., Costa J., Carvalho E.M., Barral-Netto M., and Barral A. Variation of cytokine patterns related to therapeutic response in diffuse cutaneous leishmaniasis. Exp Parasitol 84 2 (1996) 188-194
53. Castes M., and Tapia F.J. [Immunopathology of American tegumentary leishmaniasis]. Acta Cient Venez 49 1 (1998) 42-56
54. Machado P., Araujo C., Da Silva A.T., Almeida R.P., D'Oliveira Jr. A., Bittencourt A., et al. Failure of early treatment of cutaneous leishmaniasis in preventing the development of an ulcer. Clin Infect Dis 34 12 (2002) E69-E73
55. Faria D.R., Gollob K.J., Barbosa Jr. J., Schriefer A., Machado P.R., Lessa H., et al. Decreased in situ expression of interleukin-10 receptor is correlated with the exacerbated inflammatory and cytotoxic responses observed in mucosal leishmaniasis. Infect Immun 73 12 (Dec 2005) 7853-7859
56. Bittencourt A.L., and Barral A. Evaluation of the histopathological classifications of American cutaneous and mucocutaneous leishmaniasis. Mem Inst Oswaldo Cruz 86 1 (1991) 51-56
57. Antonelli L.R., Dutra W.O., Almeida R.P., Bacellar O., and Gollob K.J. Antigen specific correlations of cellular immune responses in human leishmaniasis suggests mechanisms for immunoregulation. Clin Exp Immunol 136 2 (May 2004) 341-348
58. Antonelli L.R., Dutra W.O., Almeida R.P., Bacellar O., Carvalho E.M., and Gollob K.J. Activated inflammatory T cells correlate with lesion size in human cutaneous leishmaniasis. Immunol Lett 2 (Aug 2005)
59. Almeida R., D'Oliveira Jr. A., Machado P., Bacellar O., Ko A.I., de Jesus A.R., et al. Randomized, double-blind study of stibogluconate plus human granulocyte macrophage colony-stimulating factor versus stibogluconate alone in the treatment of cutaneous leishmaniasis. J Infect Dis 180 5 (1999) 1735-1737
60. Almeida R.P., Brito J., Machado P.L., AR DEJ, Schriefer A., Guimaraes L.H., et al. Successful treatment of refractory cutaneous leishmaniasis with GM-CSF and antimonials. Am J Trop Med Hyg 73 1 (Jul 2005) 79-81
61. Lessa H.A., Machado P., Lima F., Cruz A.A., Bacellar O., Guerreiro J., et al. Successful treatment of refractory mucosal leishmaniasis with pentoxifylline plus antimony. Am J Trop Med Hyg 65 2 (2001) 87-89
62. Machado P.R., Lessa H., Lessa M., Guimaraes L.H., Bang H., Ho J.L., et al. Oral pentoxifylline combined with pentavalent antimony: a randomized trial for mucosal leishmaniasis. Clin Infect Dis 44 6 (Mar 15 2007) 788-793
63. Machado P., Kanitakis J., Almeida R., Chalon A., Araujo C., and Carvalho E.M. Evidence of in situ cytotoxicity in American cutaneous leishmaniasis. Eur J Dermatol 12 5 (Sep-Oct 2002) 449-451
64. Carvalho L.P., Passos S., Bacellar O., Lessa M., Almeida R.P., Magalhães A., et al. Differential immune regulation of activated T cells between cutaneous and mucosal leishmaniasis as a model for pathogenesis. Parasite Immunol 29 (2007) 251-258
65. Eigler A., Sinha B., Hartmann G., and Endres S. Taming TNF: strategies to restrain this proinflammatory cytokine. Immunol Today 18 10 (1997 Oct) 487-492
66. Kunkel S.L., Spengler M., Kwon G., May M.A., and Remick D.G. Production and regulation of tumor necrosis factor alpha. A cellular and molecular analysis. Methods Achiev Exp Pathol 13 (1988) 240-259
67. Sandborn W.J., and Targan S.R. Biologic therapy of inflammatory bowel disease. Gastroenterology 122 6 (2002 May) 1592-1608
68. Neuner P., Klosner G., Pourmojib M., Knobler R., and Schwarz T. Pentoxifylline in vivo and in vitro down-regulates the expression of the intercellular adhesion molecule-1 in monocytes. Immunology 90 3 (Mar 1997) 435-439
69. Amvros'eva T.V., Votiakov V.I., Andreeva O.T., Vladyko G.V., Nikolaeva S.N., Orlova S.V., et al. [New properties of trental as an inhibitor of viral activity with a wide range of activity]. Voprosy virusologii 38 5 (Sep-Dec 1993) 230-233
70. Biswas D.K., Dezube B.J., Ahlers C.M., and Pardee A.B. Pentoxifylline inhibits HIV-1 LTR-driven gene expression by blocking NF-kappa B action. J Acquir Immune Defic Syndr 6 7 (Jul 1993) 778-786
71. Navarro J., Punzon C., Jimenez J.L., Fernandez-Cruz E., Pizarro A., Fresno M., et al. Inhibition of phosphodiesterase type IV suppresses human immunodeficiency virus type 1 replication and cytokine production in primary T cells: involvement of NF-kappaB and NFAT. J Virol. 72 6 (Jun 1998) 4712-4720
72. Navarro J., Punzon M.C., Pizarro A., Fernandez-Cruz E., Fresno M., and Munoz-Fernandez M.A. Pentoxifylline inhibits acute HIV-1 replication in human T cells by a mechanism not involving inhibition of tumour necrosis factor synthesis or nuclear factor-kappa B activation. Aids 10 5 (1996 May) 469-475
73. Clerici M., Piconi S., Balotta C., Trabattoni D., Capetti A., Fusi M.L., et al. Pentoxifylline improves cell-mediated immunity and reduces human immunodeficiency virus (HIV) plasma viremia in asymptomatic HIV-seropositive persons. J Infect Dis 175 5 (1997 May) 1210-1215
74. Staak K., Prosch S., and Stein J. Pentoxifylline promotes replication of human cytomegalovirus in vivo and in vitro. Blood 89 (1997) 3682-3690
75. Ardizzoia A., Lissoni P., and Tancini G. Respiratory distress syndrome in patients with advanced cancer treated with pentoxifylline: a randomized study. Support. Care Cancer 1 6 (1993) 331-333
76. Fujimoto T., Nakamura T., Furuya T., Nakane S., Shirabe S., Kambara C., et al. Relationship between the clinical efficacy of pentoxifylline treatment and elevation of serum T helper type 2 cytokine levels in patients with human T-lymphotropic virus type I-associated myelopathy. Intern Med (Tokyo, Japan) 38 9 (Sep 1999) 717-721
77. Shirabe S., Nakamura T., Tsujino A., Nishiura Y., Furuya T., Goto H., et al. Successful application of pentoxifylline in the treatment of HTLV-I associated myelopathy. J Neurol Sci 151 1 (1997 Oct 3) 97-101
78. Bafica A., Oliveira F., Freitas L.A., Nascimento E.G., and Barral A. American cutaneous leishmaniasis unresponsive to antimonial drugs: successful treatment using combination of N-methilglucamine antimoniate plus pentoxifylline. Int J Dermatol 42 3 (Mar 2003) 203-207
79. Franke E.D., Wignall F.S., Cruz M.E., Rosales E., Tovar A.A., Lucas C.M., et al. Efficacy and toxicity of sodium stibogluconate for mucosal leishmaniasis. Ann Intern Med 113 12 (1990) 934-940
80. Sadeghian G., and Nilforoushzadeh M.A. Effect of combination therapy with systemic glucantime and pentoxifylline in the treatment of cutaneous leishmaniasis. Int J Dermatol 45 7 (Jul 2006) 819-821
81. Gessain A., Barin F., Vernant J.C., Gout O., Maurs L., Calender A., et al. Antibodies to human T-lymphotropic virus type-I in patients with tropical spastic paraparesis. Lancet 2 8452 (Aug 24 1985) 407-410
82. Suryaprasad A.G., and Prindiville T. The biology of TNF blockade. Autoimmun Rev 2 6 (Oct 2003) 346-357
83. Machuca A., Rodes B., and Soriano V. The effect of antiretroviral therapy on HTLV infection. Virus Res 78 1-2 (Oct 30 2001) 93-100
84. Izumo S., Goto I., Itoyama Y., Okajima T., Watanabe S., Kuroda Y., et al. Interferon-alpha is effective in HTLV-I-associated myelopathy: a multicenter, randomized, double-blind, controlled trial. Neurology 46 4 (1996) 1016-1021
85. Cabrera-Gomez J.A., and Lopez-Saura P. [Recent advances in the treatment the nervous system disorders with interferon-alpha]. Rev Neurol. 29 12 (Dec 16-31 1999) 1225-1235
86. Kuroda Y., Kurohara K., Fujiyama F., Takashima H., Endo C., Matsui M., et al. Systemic interferon-alpha in the treatment of HTLV-I-associated myelopathy. Acta Neurol Scand 86 1 (Jul 1992) 82-86
87. Nakagawa M., Nakahara K., Maruyama Y., Kawabata M., Higuchi I., Kubota H., et al. Therapeutic trials in 200 patients with HTLV-I-associated myelopathy/tropical spastic paraparesis. J Neurovirol 2 5 (1996 Oct) 345-355
88. Saito M., Nakagawa M., Kaseda S., Matsuzaki T., Jonosono M., Eiraku N., et al. Decreased human T lymphotropic virus type I (HTLV-I) provirus load and alteration in T cell phenotype after interferon-alpha therapy for HTLV-I-associated myelopathy/tropical spastic paraparesis. J Infect Dis 189 1 (Jan 1 2004) 29-40
89. Carod-Artal F.J., Melo M., Alves R., Brenner C., and del Negro M.C. [Potentially treatable subacute forms of infection due to the HTLV-1]. Rev Neurol 31 1 (Jul 1-15 2000) 32-35
90. Badaro R., Falcoff E., Badaro F.S., Carvalho E.M., Pedral-Sampaio D., Barral A., et al. Treatment of visceral leishmaniasis with pentavalent antimony and interferon gamma. N Engl J Med 322 1 (1990) 16-21
91. Becker I., Volkow P., Velasco-Castrejon O., Salaiza-Suazo N., Berzunza-Cruz M., Dominguez J.S., et al. The efficacy of pentamidine combined with allopurinol and immunotherapy for the treatment of patients with diffuse cutaneous leishmaniasis. Parasitol Res 85 3 (Mar 1999) 165-170
92. Santos J.B., de Jesus A.R., Machado P.R., Magalhaes A., Salgado K., Carvalho E.M., et al. Antimony plus recombinant human granulocyte-macrophage colony-stimulating factor applied topically in low doses enhances healing of cutaneous leishmaniasis ulcers: a randomized, double-blind, placebo-controlled study. J Infect Dis 190 10 (Nov 15 2004) 1793-1796
93. Ho J.L., Reed S.G., Wick E.A., and Giordano M. Granulocyte-macrophage and macrophage colony-stimulating factors activate intramacrophage killing of Leishmania mexicana amazonensis. J Infect Dis 162 1 (1990) 224-230
94. Kaplan G., Walsh G., Guido L.S., Meyn P., Burkhardt R.A., Abalos R.M., et al. Novel responses of human skin to intradermal recombinant granulocyte/macrophage-colony-stimulating factor: Langerhans cell recruitment, keratinocyte growth, and enhanced wound healing. J Exp Med 175 6 (Jun 1 1992) 1717-1728
95. Marques da Costa R., Jesus F.M., Aniceto C., and Mendes M. Double-blind randomized placebo-controlled trial of the use of granulocyte-macrophage colony-stimulating factor in chronic leg ulcers. Am J Surg 173 3 (Mar 1997) 165-168
96. Robson M., Kucukcelebi A., Carp S.S., Hayward P.G., Hui P.S., Cowan W.T., et al. Effects of granulocyte-macrophage colony-stimulating factor on wound contraction. Eur J Clin Microbiol Infect Dis 13 Suppl 2 (1994) S41-S46
97. Weiser W.Y., Van Niel A., Clark S.C., David J.R., and Remold H.G. Recombinant human granulocyte/macrophage colony-stimulating factor activates intracellular killing of Leishmania donovani by human monocyte-derived macrophages. J Exp Med 166 5 (Nov 1 1987) 1436-1446